Genentech takes the health and safety of its patients, customers, employees, and local communities very seriously, and are actively responding to the global COVID-19 pandemic. Genentech knows that needs will continue to emerge over the coming weeks and months, and they are closely monitoring and evaluating the situation as it evolves.
For more information on Genentech's response to COVID-19, please visit its website.

In a recent article from Oncology Issues, authors conducted a systematic literature review and found that two main drivers of care disparities exist for transgender and nonbinary individuals with cancer: rigid binary gender frameworks and gaps in mental health care.

2026 ACCC Innovator Award Winner St. Luke's Cancer Institute noticed a significant administrative burden being placed on providers to review medical necessity validation for complex oncology therapies. To address the resulting rise in peer-to-peer requirements, delays in care, and pre-service denials, the team designed and implemented a new Clinical Documentation Integrity Registered Nurse role.

ACCC launched its Precision Medicine Stewardship Program to highlight institutions that have successfully built the infrastructure, workflows, and leadership models needed to deliver precision medicine at scale. TriHealth Cancer and Blood Institute in Cincinnati, Ohio, offers a compelling example of what it takes to move from aspiration to execution.

Although patients with relapsed or refractory multiple myeloma now have more treatment options than ever, their journeys are often complex. As clinicians consider when to introduce newer therapies such as bispecific antibodies, they must account for prior treatments, treatment-related toxicities, and comorbidities that may impact treatment decisions.
